行情

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

实时行情|Nasdaq Last Sale

0.4251
-0.0029
-0.68%
盘后: 0.3900 -0.0351 -8.26% 19:51 08/07 EDT
开盘
0.4180
昨收
0.4280
最高
0.4300
最低
0.3820
成交量
3,289.60万
成交额
--
52周最高
0.6490
52周最低
0.1570
市值
1.68亿
市盈率(TTM)
-3.1653
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ATNM价格均价为2.750,最高价位4.000,最低价为1.500。

EPS

ATNM 新闻

更多
Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know
Zacks · 3天前
Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?
Zacks · 4天前
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know
Zacks · 07/28 22:50
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
Zacks · 07/27 16:30
Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy?
Zacks · 07/23 17:00
Implied Volatility Surging for Actinium Pharmaceuticals (ATNM) Stock Options
Zacks · 07/21 13:57
Actinium Pharmaceuticals, Inc. (ATNM) Shares March Higher, Can It Continue?
Zacks · 07/20 15:32
Actinium Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Zacks · 07/15 12:03

所属板块

生物技术和医学研究
-0.18%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

ATNM 简况

Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
展开

微牛提供Actinium Pharmaceuticals Inc(AMEX-ATNM)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ATNM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ATNM股票基本功能。